MEMBER LOGIN: Your Email: Password: Remember Me
Forgot Your Password or would like to register?
SGEN Seattle Genetics
As Of 7/18/2018 7:11:00 PM
Current Price$68.03
Current Rating6
Return Since 8/2015
Seattle Genetics42.11 %
S&P 50033.52 %
VFS Rating Analysis
Related Links
Company News
Earnings Call Transcripts
Options Chain
Options Pricing History
For current estimates, historical performance information and more, Log in to your account.

Monthly Performance and Prediction History
Below is the monthly performance history for this security and the monthly change as compared to the stock market for this security. When a row is highlighted in green, it is identifying a stock that the model predict will outperform the portfolio for that month. When a row is highlighted in red, it is identifying a stock that the model predicted will underperform for the month. No highlight indicates the model is neutral on the stock. These predictions are always recorded at the beginning of the month, and table below shows the resulting return for the month.
DateVFS RatingPredictionRating PriceSubsequent
% Increase
Market %
Increase *
7-01-20186 $66.39   
* As measured by the performance of the S&P 500 for the month.

SGEN25Blog Exposure - Seattle Genetics Announces First Patient Dosage in Phase-2 innovaTV 207 Trial for Multiple Solid Tumors ( 4:40:00 AM
SGEN25Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors ( 5:00:00 AM
SGEN25Seattle Genetics and Astellas Announce Progress in Enfortumab Vedotin Urothelial Cancer Clinical Development Program ( 5:00:00 AM
SGEN20CORRECTING and REPLACING Seattle Genetics Announces Publication of Results from Two Tucatinib Phase 1b Clinical Trials in HER2-Positive Metastatic Breast Cancer ( 7:41:00 AM
SGEN20See what the IHS Markit Score report has to say about Seattle Genetics Inc. ( 5:07:00 AM
SGEN15Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering ( 5:35:00 AM
SGEN15Breakfast Technical Briefing on Tetraphase Pharma and Three Other Additional Biotech Stocks ( 4:20:00 AM
SGEN15Cramer's lightning round: Amazon doesn't always destroy—just look at Roku ( 3:51:00 PM
SGEN15How Analysts Are Rating Puma Biotechnology in July ( 6:38:00 AM
AMZN, SGEN1Cramer's lightning round: Amazon doesn't always destroy—just look at Roku ( 3:51:00 PM

WEBSITE DISCLAIMER:  Puget Investors and Vertical Financial Systems, Inc are not registered investment advisers, broker/dealers, or research analysts/organizations. The content on this website is issued solely for information purposes and should not to be construed as an offer to buy, sell, or trade in any way, any security mentioned herein.

All information presented on this website is believed to be reliable and written in good faith, but no representation or warranty, expressed or implied is made as to their accuracy, completeness or correctness. You are responsible for doing your own research before investing in any securities mentioned herein. Readers are urged to consult with their own independent financial advisors with respect to any investment. Neither Vertical Financial Systems, Inc, nor its officers or employees accept any liability whatsoever for any direct or consequential loss arising from any use of information on this website.

Past performance is not a guarantee of future performance or accuracy. Rating calculations and methodology may change at any time, and we reserve the right to make changes which may impact the accuracy of the model without prior notice to anybody.

Be advised that employees and officers of Vertical Financial Systems, Inc and may hold positions in the securities mentioned in this website.
Website Operated by Vertical Financial Systems, Inc